Advertisement

Advertisement

Departments

Advertisement

Advertisement

Jan

22

Today In Oncology

Does Proton Pump Inhibitor Use Affect Cognition in Breast Cancer Survivors?

Using T-Cell Fraction to Predict Melanoma Recurrence

irAEs and Recurrence-Free Survival With Adjuvant Immunotherapy vs Placebo in Stage III Melanoma

Extended Letrozole Boosts Disease-Free Survival in 10-Year Update of NSABP B-42 Trial

Brentuximab Vedotin Plus Nivolumab in Hodgkin Lymphoma

Advertisement

Most Read Stories

FDA Pipeline: Priority Reviews in Ovarian Cancer, Prostate Cancer, and NSCLC

Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous NSCLC

When Can Patients With Gleason 6 Prostate Cancer Safely Undergo Active Surveillance?

How I Work up the Patient with Thrombocytosis

Use of Artificial Intelligence for Diagnosing and Grading Prostate Cancer

Most Viewed Videos

Rashmi K. Murthy, MD, on HER2-Positive Metastatic Breast Cancer: HER2CLIMB Trial of Tucatinib, Capecitabine, and Trastuzumab

Solange Peters, MD, PhD, on NSCLC: CheckMate 227 Trial of Nivolumab/Ipilimumab vs Chemotherapy

Nicoletta Colombo, MD, on Lenvatinib/Pembrolizumab for Advanced Endometrial Cancer

Francesca Battaglin, MD, on Colorectal Cancer: Using Genetic Variants to Predict Treatment Efficacy

Nadine M. Tung, MD, on HER2-Negative Breast Cancer: INFORM Trial of Cisplatin vs Doxorubicin/Cyclophosphamide

© 2020 HSP News Service, L.L.C.